Cargando…
A Refined Staging Model for Resectable Pancreatic Ductal Adenocarcinoma Incorporating Examined Lymph Nodes, Location of Tumor and Positive Lymph Nodes Ratio
Background: Nodal status and tumor site are prognostic factors for resectable pancreatic ductal adenocarcinoma (PDAC). Parameters for nodal status are diverse, and the number of examined lymph nodes (eNs) needed for good prognosis are uncertain. We try to modify staging system of resectable PDAC wit...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171033/ https://www.ncbi.nlm.nih.gov/pubmed/30310507 http://dx.doi.org/10.7150/jca.26187 |
_version_ | 1783360723118718976 |
---|---|
author | Song, Yunda Chen, Zhenxin Chen, Luohai He, Chaobin Huang, Xin Duan, Fangting Wang, Jun Lao, Xiangming Li, Shengping |
author_facet | Song, Yunda Chen, Zhenxin Chen, Luohai He, Chaobin Huang, Xin Duan, Fangting Wang, Jun Lao, Xiangming Li, Shengping |
author_sort | Song, Yunda |
collection | PubMed |
description | Background: Nodal status and tumor site are prognostic factors for resectable pancreatic ductal adenocarcinoma (PDAC). Parameters for nodal status are diverse, and the number of examined lymph nodes (eNs) needed for good prognosis are uncertain. We try to modify staging system of resectable PDAC with parameters mentioned above by recursive partitioning analysis. Methods: Patients from the Surveillance, Epidemiology, and End Results (SEER) database were divided into training cohort and internal validation cohort, randomly. PDAC patients from Sun Yat-sen University Cancer Center were regarded as external validation cohort. The training cohort was used to refine staging model by recursive partitioning analysis, while the internal validation cohort and the external validation cohort were applied to assess discriminatory capacity of staging model. For parameters included in the modified model, their effects were studied. Results: The number of eNs, tumor site and tumor size were risk factors for positive nodal status. Lymph nodes ratio (LNR), tumor site, eNs and T stages of 8(th) the American Joint Committee on Cancer (AJCC) were selected to develop a refined model, dividing patients into 5 groups of different outcomes, preceding 8(th) AJCC classification. Besides, we found that (1) for small PDAC (diameter < 1cm), lymph node metastasis was rarely found; (2) enough eNs were needed to ensure better prognosis of node-negative patients; (3) tumors in the head of pancreas were prone to lymph nodes metastasis; (4) for node-positive patients, LNR was a better nodal parameter compared to positive lymph nodes (pNs). Conclusion: Our improved staging system helps to illuminate the interactions among tumor site, size and eNs. |
format | Online Article Text |
id | pubmed-6171033 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-61710332018-10-11 A Refined Staging Model for Resectable Pancreatic Ductal Adenocarcinoma Incorporating Examined Lymph Nodes, Location of Tumor and Positive Lymph Nodes Ratio Song, Yunda Chen, Zhenxin Chen, Luohai He, Chaobin Huang, Xin Duan, Fangting Wang, Jun Lao, Xiangming Li, Shengping J Cancer Research Paper Background: Nodal status and tumor site are prognostic factors for resectable pancreatic ductal adenocarcinoma (PDAC). Parameters for nodal status are diverse, and the number of examined lymph nodes (eNs) needed for good prognosis are uncertain. We try to modify staging system of resectable PDAC with parameters mentioned above by recursive partitioning analysis. Methods: Patients from the Surveillance, Epidemiology, and End Results (SEER) database were divided into training cohort and internal validation cohort, randomly. PDAC patients from Sun Yat-sen University Cancer Center were regarded as external validation cohort. The training cohort was used to refine staging model by recursive partitioning analysis, while the internal validation cohort and the external validation cohort were applied to assess discriminatory capacity of staging model. For parameters included in the modified model, their effects were studied. Results: The number of eNs, tumor site and tumor size were risk factors for positive nodal status. Lymph nodes ratio (LNR), tumor site, eNs and T stages of 8(th) the American Joint Committee on Cancer (AJCC) were selected to develop a refined model, dividing patients into 5 groups of different outcomes, preceding 8(th) AJCC classification. Besides, we found that (1) for small PDAC (diameter < 1cm), lymph node metastasis was rarely found; (2) enough eNs were needed to ensure better prognosis of node-negative patients; (3) tumors in the head of pancreas were prone to lymph nodes metastasis; (4) for node-positive patients, LNR was a better nodal parameter compared to positive lymph nodes (pNs). Conclusion: Our improved staging system helps to illuminate the interactions among tumor site, size and eNs. Ivyspring International Publisher 2018-09-08 /pmc/articles/PMC6171033/ /pubmed/30310507 http://dx.doi.org/10.7150/jca.26187 Text en © Ivyspring International Publisher This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Research Paper Song, Yunda Chen, Zhenxin Chen, Luohai He, Chaobin Huang, Xin Duan, Fangting Wang, Jun Lao, Xiangming Li, Shengping A Refined Staging Model for Resectable Pancreatic Ductal Adenocarcinoma Incorporating Examined Lymph Nodes, Location of Tumor and Positive Lymph Nodes Ratio |
title | A Refined Staging Model for Resectable Pancreatic Ductal Adenocarcinoma Incorporating Examined Lymph Nodes, Location of Tumor and Positive Lymph Nodes Ratio |
title_full | A Refined Staging Model for Resectable Pancreatic Ductal Adenocarcinoma Incorporating Examined Lymph Nodes, Location of Tumor and Positive Lymph Nodes Ratio |
title_fullStr | A Refined Staging Model for Resectable Pancreatic Ductal Adenocarcinoma Incorporating Examined Lymph Nodes, Location of Tumor and Positive Lymph Nodes Ratio |
title_full_unstemmed | A Refined Staging Model for Resectable Pancreatic Ductal Adenocarcinoma Incorporating Examined Lymph Nodes, Location of Tumor and Positive Lymph Nodes Ratio |
title_short | A Refined Staging Model for Resectable Pancreatic Ductal Adenocarcinoma Incorporating Examined Lymph Nodes, Location of Tumor and Positive Lymph Nodes Ratio |
title_sort | refined staging model for resectable pancreatic ductal adenocarcinoma incorporating examined lymph nodes, location of tumor and positive lymph nodes ratio |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171033/ https://www.ncbi.nlm.nih.gov/pubmed/30310507 http://dx.doi.org/10.7150/jca.26187 |
work_keys_str_mv | AT songyunda arefinedstagingmodelforresectablepancreaticductaladenocarcinomaincorporatingexaminedlymphnodeslocationoftumorandpositivelymphnodesratio AT chenzhenxin arefinedstagingmodelforresectablepancreaticductaladenocarcinomaincorporatingexaminedlymphnodeslocationoftumorandpositivelymphnodesratio AT chenluohai arefinedstagingmodelforresectablepancreaticductaladenocarcinomaincorporatingexaminedlymphnodeslocationoftumorandpositivelymphnodesratio AT hechaobin arefinedstagingmodelforresectablepancreaticductaladenocarcinomaincorporatingexaminedlymphnodeslocationoftumorandpositivelymphnodesratio AT huangxin arefinedstagingmodelforresectablepancreaticductaladenocarcinomaincorporatingexaminedlymphnodeslocationoftumorandpositivelymphnodesratio AT duanfangting arefinedstagingmodelforresectablepancreaticductaladenocarcinomaincorporatingexaminedlymphnodeslocationoftumorandpositivelymphnodesratio AT wangjun arefinedstagingmodelforresectablepancreaticductaladenocarcinomaincorporatingexaminedlymphnodeslocationoftumorandpositivelymphnodesratio AT laoxiangming arefinedstagingmodelforresectablepancreaticductaladenocarcinomaincorporatingexaminedlymphnodeslocationoftumorandpositivelymphnodesratio AT lishengping arefinedstagingmodelforresectablepancreaticductaladenocarcinomaincorporatingexaminedlymphnodeslocationoftumorandpositivelymphnodesratio AT songyunda refinedstagingmodelforresectablepancreaticductaladenocarcinomaincorporatingexaminedlymphnodeslocationoftumorandpositivelymphnodesratio AT chenzhenxin refinedstagingmodelforresectablepancreaticductaladenocarcinomaincorporatingexaminedlymphnodeslocationoftumorandpositivelymphnodesratio AT chenluohai refinedstagingmodelforresectablepancreaticductaladenocarcinomaincorporatingexaminedlymphnodeslocationoftumorandpositivelymphnodesratio AT hechaobin refinedstagingmodelforresectablepancreaticductaladenocarcinomaincorporatingexaminedlymphnodeslocationoftumorandpositivelymphnodesratio AT huangxin refinedstagingmodelforresectablepancreaticductaladenocarcinomaincorporatingexaminedlymphnodeslocationoftumorandpositivelymphnodesratio AT duanfangting refinedstagingmodelforresectablepancreaticductaladenocarcinomaincorporatingexaminedlymphnodeslocationoftumorandpositivelymphnodesratio AT wangjun refinedstagingmodelforresectablepancreaticductaladenocarcinomaincorporatingexaminedlymphnodeslocationoftumorandpositivelymphnodesratio AT laoxiangming refinedstagingmodelforresectablepancreaticductaladenocarcinomaincorporatingexaminedlymphnodeslocationoftumorandpositivelymphnodesratio AT lishengping refinedstagingmodelforresectablepancreaticductaladenocarcinomaincorporatingexaminedlymphnodeslocationoftumorandpositivelymphnodesratio |